Today: 11 April 2026
Subscribe
Browse Category

Pharmaceuticals 10 February 2026 - 15 February 2026

AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie stock ends higher Friday; what traders watch for ABBV after the Presidents Day break

AbbVie shares closed up 1.8% at $231.50 Friday, outpacing Johnson & Johnson. U.S. markets will be closed Monday for Presidents Day, with trading set to resume Tuesday. Investors are weighing AbbVie’s drug-pricing moves and pipeline as the company shifts away from Humira after patent loss. Trading volume topped its recent average, with the stock about 5% below its 52-week high.
15 February 2026
··
Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

Healthcare stocks head into Presidents Day break after Dexcom, Moderna lift XLV

The Health Care Select Sector SPDR Fund (XLV) rose 1.1% to $157.67 Friday, led by Dexcom’s 7.6% jump and Moderna’s 5.3% gain after earnings. Dexcom beat Q4 estimates and reiterated its 2026 outlook, while Moderna forecast up to 10% revenue growth, citing overseas markets. Broader markets saw tech lag as inflation data cooled. U.S. exchanges close Monday for Presidents Day.
15 February 2026
··
Vertex stock jumps nearly 6% on Oppenheimer upgrade as traders size up new drug pipeline

Vertex stock jumps nearly 6% on Oppenheimer upgrade as traders size up new drug pipeline

Vertex shares jumped 5.7% to $491.47 Friday after Oppenheimer upgraded the stock, citing growth plans beyond cystic fibrosis. The company set 2026 revenue guidance at up to $13.1 billion, with at least $500 million expected from new products. Vertex highlighted gene-editing, pain, and kidney therapies in its outlook. U.S. markets close Monday for Presidents Day.
14 February 2026
··
Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna stock price jumps late after earnings beat, but FDA flu setback hangs over MRNA

Moderna shares climbed 5% to $42.23 in after-hours trading Friday after beating fourth-quarter revenue estimates and reaffirming its 2026 growth outlook. The FDA refused to file Moderna’s flu vaccine application, prompting the company to seek a Type A meeting. The flu shot is under review in Europe, Canada, and Australia. Moderna reported Q4 revenue of $678 million and a $2.11 per share loss.
13 February 2026
····
Merck stock pops on Deutsche Bank upgrade — what to watch ahead of ASCO GU

Merck stock pops on Deutsche Bank upgrade — what to watch ahead of ASCO GU

Merck shares climbed 1.8% to $121.41 in after-hours trading Friday after Deutsche Bank upgraded the stock and raised its price target. The move comes ahead of key cancer study results set for release at the ASCO Genitourinary Cancers Symposium later this month. Merck’s chief marketing officer sold 10,000 shares on Feb. 12. U.S. markets are closed Monday for Washington’s Birthday; trading resumes Tuesday.
13 February 2026
··
Eli Lilly stock price climbs as $1.5 billion pill stockpile sharpens focus on FDA April decision

Eli Lilly stock price climbs as $1.5 billion pill stockpile sharpens focus on FDA April decision

Eli Lilly shares rose 0.6% to $1,044.62 after the company disclosed $1.5 billion in pre-launch inventory for its experimental obesity pill, orforglipron, ahead of an expected FDA decision in April. The company also repurchased $4.1 billion in shares in 2025 and raised its quarterly dividend. Chinese regulators approved Lilly’s mirikizumab for Crohn’s disease and ulcerative colitis. U.S. stocks slipped in midday trading.
13 February 2026
··
Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

Eli Lilly stock climbs near 2%: China drug approval and GLP-1 pill race in focus

Eli Lilly shares rose 1.8% to $1,033.23 in late morning New York trade after Chinese regulators approved mirikizumab for Crohn’s disease and ulcerative colitis. Investors are watching a Feb. 13 ex-dividend date and an expected U.S. decision in April on Lilly’s oral weight-loss pill. Novo Nordisk shares slipped as it announced plans to launch Wegovy in vials.
12 February 2026
··
Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer stock slips before the open after a run to $27.73 — here’s what’s driving PFE now

Pfizer shares slipped 0.3% to $27.52 in premarket trading Wednesday after a 2.1% gain the previous session. The company agreed to a $29 million settlement with the SEC over a 2013 insider-trading case tied to SAC Capital, pending court approval. Pfizer joined Swiss biotech incubator BaseLaunch as a partner. Investors await Friday’s U.S. consumer price index report.
11 February 2026
···
AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie shares rose 0.7% to $224.83 Tuesday afternoon, near the session high, after BNP Paribas Exane raised its price target to $213 but kept a neutral rating. The stock traded in a narrow range as investors awaited delayed U.S. payrolls and inflation data for rate signals. U.S. stocks were mixed, with the Dow at a record high and S&P 500 little changed.
10 February 2026
··
Merck stock price slips after insider sale filings; what MRK investors are watching next

Merck stock price slips after insider sale filings; what MRK investors are watching next

Merck shares fell 0.5% to $117.01 after SEC filings showed insider stock sales by two executives on Feb. 9. Chief Marketing Officer Chirfi Guindo sold 10,000 shares; Executive Vice President Jennifer Zachary exercised and sold 121,573 shares. The moves followed a revenue forecast below Wall Street estimates. Merck underperformed the broader market and sector peers.
10 February 2026
··
Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers Health shares fell 5.6% to $18.25 Tuesday after Novo Nordisk filed a U.S. patent lawsuit seeking to block sales of compounded versions of its Wegovy weight-loss drug. The FDA has said semaglutide is no longer in shortage, tightening rules on compounding. Hims pulled its $49 compounded semaglutide pill days after launch. Investors await Hims’ earnings on Feb. 23.
10 February 2026
···
Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention

Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention

Eli Lilly shares fell 0.9% to $1,035.54 Tuesday morning after new deals in cell therapy and China drug development. The company agreed to buy Orna Therapeutics for up to $2.4 billion and struck a collaboration with Innovent Biologics. Investors weighed increased pipeline spending as competition in obesity drugs intensified. Attention turns to an upcoming FDA decision on Lilly’s oral obesity pill.
10 February 2026
··
Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Hims & Hers Health shares dropped 4.2% to $18.52 premarket Tuesday after plunging 16% Monday. The company halted its compounded semaglutide pill following warnings from U.S. regulators and a new patent lawsuit by Novo Nordisk. The FDA signaled plans to restrict non-approved GLP-1 drugs and may take legal action. The Department of Health and Human Services referred Hims to the Justice Department.
10 February 2026
···
1 2 3 4 5 … 38

Stock Market Today

  • ServiceNow (NOW) Stock Drops 9.4% Amid UBS Downgrade and AI Competition Concerns
    April 10, 2026, 10:39 PM EDT. Shares of ServiceNow (NYSE: NOW) slid 9.4% after UBS downgraded the stock from Buy to Neutral, cutting the price target to $100. UBS analysts cited worries about ServiceNow losing its competitive edge as companies shift spending from traditional software to AI tools. The stock has been volatile, with 11 swings over 5% in the past year. It's now trading 60.7% below its 52-week high, down 44.3% year-to-date. Recent AI developments, including Anthropic's Managed Agents and commentary from short seller Michael Burry, have raised concerns about disruption to legacy Software-as-a-Service models. Despite the drop, the move may reflect market noise rather than a fundamental change in ServiceNow's outlook.

Latest article

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 10:48 PM EDT ServiceNow (NOW) Stock Drops 9.4% Amid UBS Downgrade and AI Competition Concerns April 10, 2026, 10:39 PM EDT. Shares of ServiceNow (NYSE: NOW) slid 9.4% after UBS downgraded the stock from Buy to Neutral, cutting the price target to $100. UBS analysts cited worries about ServiceNow losing its competitive edge as companies shift spending from traditional software to AI tools. The stock has been volatile, with 11 swings over 5% in the past year. It's now trading 60.7% below its 52-week high, down 44.3% year-to-date.
MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
Go toTop